Last reviewed · How we verify
NCT06379282: HIT-CLL
Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia
NA trial testing HIT in Chronic Lymphocytic Leukemia in 132 participants. Currently enrolling.
1 August 2025
Quick facts
| Lead sponsor | University of Surrey |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 132 |
| Start date | 14 October 2022 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- HIT
- EXE+ Nutritional Guidance
Conditions studied
- Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
- Frailty — all drugs for Frailty →
- Muscle Function — all drugs for Muscle Function →
- Immune Function — all drugs for Immune Function →
Sponsor
University of Surrey
Who can join
18 and older, any sex, with Chronic Lymphocytic Leukemia or Frailty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia. Investigators will randomise participants to either 12 weeks of supervised/semi-supervised exercise only, exercise + nutritional guidance, or no exercise.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06379282
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HIT
Trials testing the same drug.
- NCT03545841 — HIT in People With Type 1 Diabetes · NA · completed
Other recruiting trials for Chronic Lymphocytic Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
- NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
- NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
- NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting
Other University of Surrey trials
Trials by the same sponsor.
- NCT07251257 — The Seafarers' Continuous Glucose Monitoring Systems Study · recruiting
- NCT06930924 — Supporting Children and Young People to Live Well With Coeliac Disease: A RCT · NA · not yet recruiting
- NCT06775795 — The Bioavailability of Iodine in Plant-based Milk Alternatives · NA · active not recruiting
- NCT06007898 — Supporting Children and Young People to Live Well with Coeliac Disease · NA · completed
- NCT07375420 — Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer? · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06379282 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Surrey
- Last refreshed: 24 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06379282.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing